Related Experiment Video
Updated: Apr 9, 2026
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease
Joseph El Khoury1, Michelle Toft, Suzanne E Hickman
1Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, Massachusetts 02129, USA. jelkhoury@partners.org
Abstract:
Microglia are the principal immune cells of the brain. In Alzheimer disease, these brain mononuclear phagocytes are recruited from the blood and accumulate in senile plaques. However, the role of microglia in Alzheimer disease has not been resolved. Microglia may be neuroprotective by phagocytosing amyloid-beta (Abeta), but their activation and the secretion of neurotoxins may also cause neurodegeneration. Ccr2 is a chemokine receptor expressed on microglia, which mediates the accumulation of mononuclear phagocytes at sites of inflammation. Here we show that Ccr2 deficiency accelerates early disease progression and markedly impairs microglial accumulation in a transgenic mouse model of Alzheimer disease (Tg2576). Alzheimer disease mice deficient in Ccr2 accumulated Abeta earlier and died prematurely, in a manner that correlated with Ccr2 gene dosage, indicating that absence of early microglial accumulation leads to decreased Abeta clearance and increased mortality. Thus, Ccr2-dependent microglial accumulation plays a protective role in the early stages of Alzheimer disease by promoting Abeta clearance.
Insights
Chemokine receptor Ccr2 deficiency accelerates Alzheimer disease progression by impairing microglial accumulation and amyloid-beta clearance. Ccr2-dependent microglial recruitment is crucial for early disease management and survival.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Microglia are key brain immune cells implicated in Alzheimer disease (AD).
- Their role in AD pathogenesis is debated: potentially neuroprotective via amyloid-beta (Abeta) phagocytosis or neurotoxic through inflammatory mediators.
- Ccr2, a chemokine receptor on microglia, guides mononuclear phagocyte accumulation at inflammation sites.
Purpose of the Study:
- To investigate the role of Ccr2-mediated microglial accumulation in an Alzheimer disease mouse model.
- To determine if Ccr2 deficiency impacts disease progression and Abeta clearance.
Main Methods:
- Utilized a transgenic mouse model of Alzheimer disease (Tg2576).
- Compared disease progression and microglial accumulation in Ccr2-deficient AD mice versus wild-type AD mice.
- Assessed Abeta accumulation and mortality rates in relation to Ccr2 gene dosage.
Main Results:
- Ccr2 deficiency significantly accelerated early Alzheimer disease progression in Tg2576 mice.
- Impaired microglial accumulation was observed in Ccr2-deficient AD mice.
- Mice lacking Ccr2 accumulated Abeta earlier and exhibited increased premature mortality, correlating with Ccr2 gene dosage.
Conclusions:
- Ccr2-dependent microglial accumulation plays a critical protective role in the early stages of Alzheimer disease.
- Promoting microglial recruitment via Ccr2 enhances Abeta clearance and reduces mortality.
- Targeting Ccr2 may offer a therapeutic strategy for improving early AD outcomes.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
06:43A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
Published on: February 5, 2018
